ArticleCancers2020
Predictive Features of Malignancy in Branch Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Meta-Analysis.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-derived cancer and concomitant pancreatic ductal adenocarcinoma.Japanese journal of radiology · 2026Review
- Pancreatic Cancer Detection in Intraductal Papillary Mucinous Neoplasm (IPMN)-New Insights.Cancers · 2025Review
- Risk Factor and Prediction Model for Malignant Transformation in Pancreatic Intraductal Papillary Mucinous Neoplasm.Cancer medicine · 2025Article
- Current Considerations in Nonoperative Surveillance of Intraductal Papillary Mucinous Neoplasms.Digestive disease interventions · 2025Article
- Article
- A Comparison of Single Dimension and Volume Measurements in the Risk Stratification of Pancreatic Cystic Lesions.Journal of clinical medicine · 2023Review
- Pancreatic Cystic Neoplasms: Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2023Review
- Nomogram to predict malignancy in branch duct type intraductal papillary mucinous neoplasms.Medicine · 2022Article
- Pancreatic intraductal papillary mucinous neoplasms: Current diagnosis and management.World journal of gastrointestinal oncology · 2021Review
- Surgical Treatment of Pancreatic Ductal Adenocarcinoma.Cancers · 2021Article
- The Ratio of C-Reactive Protein to Albumin Is an Independent Predictor of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas.Journal of clinical medicine · 2021Article
- A Review of the Diagnosis and Management of Premalignant Pancreatic Cystic Lesions.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current guidelines on branch duct type intraductal papillary mucinous neoplasm (BD-IPMN) recommend various predictive features of malignancy as well as different treatment strategies. This study aimed to identify the risk factors for malignancy with higher level of evidence. A meta-analysis was performed on 40 literatures published between 2000 and 2019. These literatures included 6301 patients with pathologically proven IPMN. Malignancy was defined as high-grade dysplasia and invasive carcinoma. It was significantly associated with symptoms (odds ratio [OR] 1.35, confidence interval [CI] 1.01-1.79), size ≥ 3 cm (OR 1.90, CI 1.51-2.40), cystic wall thickening (OR 2.53, CI 1.50-4.27), mural nodule (OR 4.10, CI 3.38-4.97), main pancreatic duct dilatation (OR 2.98, CI 2.11-4.21), abrupt caliber change of the pancreatic duct (OR 7.41, CI 2.49-22.06), lymphadenopathy (OR 8.55, CI 3.25-22.51), elevated carbohydrate antigen 19-9 (OR 4.01, CI 2.55-6.28), and elevated carcinoembryonic antigen (OR 2.04, CI 1.60-2.61). Multilocular cysts and multiple cysts did not show a significant association with malignancy. This study examined the clinical, radiological, and biochemical features of BD-IPMN, often used as malignancy predictors according to the widely used guidelines. The results confirmed that all the features currently being used are valid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.